SHANGHAI, CHINA--(Marketwire - November 29, 2007) - Sinobiomed Inc. (“Sinobiomed”, or “the Company”) (OTCBB: SOBM) is pleased to update on clinical trial progress for four products in the Company’s development pipeline made by the Company’s 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (“Shanghai Wanxing”): its malaria candidate vaccine, recombinant batroxobin (rBAT), Etheophazine and recombinant human kallikrein 1 (rhK1).
